|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 原发性肺癌诊疗规范(2018年版)显示文摘1,概述,原发性肺癌(primary lung cancer,PLC)是世界范围内最常见的恶性肿瘤。从病理和治疗角度,肺癌大致可以分为非小细胞肺癌(non small celllung cancer,NSCLC)和小细胞肺癌(small celllung cancer,SCLC)两大类,其中非小细胞肺癌约占80%~85%,其余为小细胞肺癌。由于小细胞肺癌独特的生物学行为,治疗上除了少数早期病例外,主要采用化疗和放疗结合的综合治疗。如果没有特别说明,肺癌指代非小细胞肺癌. | | 2019 | 肿瘤综合治疗电子杂志2019，5，3： | 113 |
| 2 | Ulinastatin for acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis显示文摘AIM: To investigate the efficacy and safety of ulinastatin for patients with acute lung injury(ALI) and those with acute respiratory distress syndrome(ARDS).METHODS: A systematic review of randomized controlled trials(RCTs) of ulinastatin for ALI/ARDS was conducted. Oxygenation index, mortality rate [intensive care unit(ICU) mortality rate, 28-d mortality rate] and length of ICU stay were compared between ulinastatin group and conventional therapy group. Meta-analysis was performed by using Rev Man 5.1.RESULTS: Twenty-nine RCTs with 1726 participants were totally included, the basic conditions of which were similar. No studies discussed adverse effect. Oxygenation index was reported in twenty-six studies(1552 patients). Ulinastatin had a significant effect in improving oxygenation [standard mean difference(SMD) = 1.85, 95%CI: 1.42-2.29, P < 0.00001, I2 = 92%]. ICUmortality and 28-d mortality were respectively reported in eighteen studies(987 patients) and three studies(196 patients). We found that ulinastatin significantly decreased the ICU mortality [I2 = 0%, RR = 0.48, 95%CI: 0.38-0.59, number needed to treat(NNT) = 5.06, P < 0.00001], while the 28-d mortality was not significantly affected(I2 = 0%, RR = 0.78, 95%CI: 0.51-1.19, NNT = 12.66, P = 0.24). The length of ICU stay(six studies, 364 patients) in the ulinastatin group was significantly lower than that in the control group(SMD =-0.97, 95%CI:-1.20--0.75, P < 0.00001, I2 = 86%). CONCLUSION: Ulinastatin seems to be effective for ALI and ARDS though most trials included were of poor quality and no information on safety was provided. | Yu-Xin Leng Shu-Guang Yang Ya-Han Song Xi Zhu Gai-Qi Yao | 2014 | World Journal of Critical Care Medicine2014，3，1： | 61 |
| 3 | 急性肺损伤/急性呼吸窘迫综合征发病机制研究进展显示文摘急性肺损伤(acute lung injury,ALI)/急性呼吸窘迫综合征(acute respiratory distress syndrome,ARDS)是各种肺内、肺外致病因素导致的急性弥漫性炎症性肺损伤,进而引起急性呼吸衰竭,以肺血管通透性增高、肺泡腔渗出富含蛋白质的液体、肺水肿及透明膜的形成为主要病理特征。 | 伍冬冬 潘频华 覃庆武 | 2015 | 中华结核和呼吸杂志2015，38，7： | 46 |
| 4 | Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment显示文摘Objective:Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor,fibroblast growth factor receptor,platelet-derived growth factor receptor,c-Kit,and c-MET;therefore,it exhibits both antitumor and anti-angiogenetic activities.A phase III trial has shown that anlotinib improved progression-free survival(PFS)and overall survival(OS)in patients with advanced non-small cell lung cancer(NSCLC),who presented with progressive disease or intolerance after standard chemotherapy.This study aimed to analyze the characteristics of patients receiving anlotinib treatment to determine the dominant populations who are fit for the treatment.Methods:Data were collected from March 2015 to January 2017 from a randomized,double-blind,placebo-controlled,multicenter,phase III trial of anlotinib(ALTER0303).A total of 437 patients were enrolled and randomly allocated(2:1)to the anlotinib and placebo groups.Kaplan–Meier analysis and log-rank test were performed to compare PFS and OS.Cox proportional hazards model was adopted for multivariate prognostic analysis.Results:Multivariate analysis indicated that high post-therapeutic peripheral blood granulocyte/lymphocyte ratio and elevated alkaline phosphatase levels were independent risk factors for PFS.Meanwhile,elevated thyroid-stimulating hormone,blood glucose,and triglyceride levels;hypertension;and hand–foot syndrome were independent protective factors of PFS.High posttherapeutic peripheral blood granulocyte/lymphocyte ratio,an Eastern Cooperative Oncology Group(ECOG)score≥2,and the sum of the maximal target lesion length at baseline were independent risk factors of OS,and hypertriglyceridemia was an independent protective factor of OS.Conclusions:This study preliminarily explored the possible factors that affected PFS and OS after anlotinib treatment in patients with advanced refractory NSCLC,and the baseline characteristics of the therapeutically dominant populations were then identified. | Jing Wang Yizhuo Zhao Qiming Wang Li Zhang Jianhua Shi Zhehai Wang Ying Cheng Jianxing He Yuankai Shi Hao Yu Yang Zhao Weiqiang Chen Yi Luo Xiuwen Wang Kejun Nan Faguang Jin Jian Dong Baolan Li Zhujun Liu Baohui Han Kai Li | 2018 | Cancer Biology & Medicine2018，15，4： | 46 |
| 5 | Erianin,a novel dibenzyl compound in Dendrobium extract,inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis显示文摘Ferroptosis,a novel form of programmed cell death,is characterized by iron-dependent lipid peroxidation and has been shown to be involved in multiple diseases,including cancer.Stimulating ferroptosis in cancer cells may be a potential strategy for cancer therapy.Therefore,ferroptosis-inducing drugs are attracting more attention for cancer treatment.Here,we showed that erianin,a natural product isolated from Dendrobium chrysotoxum Lindl,exerted its anticancer activity by inducing cell death and inhibiting cell migration in lung cancer cells.Subsequently,we demonstrated for the first time that erianin induced ferroptotic cell death in lung cancer cells,which was accompanied by ROS accumulation,lipid peroxidation,and GSH depletion.The ferroptosis inhibitors Fer-1 and Lip-1 but not Z-VAD-FMK,CQ,or necrostatin-1 rescued erianin-induced cell death,indicating that ferroptosis contributed to erianin-induced cell death.Furthermore,we demonstrated that Ca^(2+)/CaM signaling was a critical mediator of erianin-induced ferroptosis and that blockade of this signaling significantly rescued cell death induced by erianin treatment by suppressing ferroptosis.Taken together,our data suggest that the natural product erianin exerts its anticancer effects by inducing Ca^(2+)/CaMdependent ferroptosis and inhibiting cell migration,and erianin will hopefully serve as a prospective compound for lung cancer treatment. | Peng Chen Qibiao Wu Jiao Feng Lili Yan Yitian Sun Shuiping Liu Yu Xiang Mingming Zhang Ting Pan Xiaying Chen Ting Duan Lijuan Zhai Bingtao Zhai Wengang Wang Ruonan Zhang Bi Chen Xuemeng Han Yicong Li Liuxi Chen Ying Liu Xingxing Huang Ting Jin Wenzheng Zhang Hong Luo Xiaohui Chen Yongqiang Li Qiujie Li Guohua Li Qin Zhang Lvjia Zhuo Zuyi Yang Huifen Tang Tian Xie Xiaoping Ouyang Xinbing Sui | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 42 |
| 6 | 浅析2006年慢性阻塞性肺疾病全球创议修订版显示文摘2006年11月19日Global Initiative for Chronic Obstructive Lung Disease(GOLD)执行委员会在日本京都颁布了新的慢性阻塞性肺疾病全球创议(GOLD)。新修订版的GOLD在总结最新研究成果的基础上对2005年版GOLD进行了修改和补充,现浅述如下: | 徐凌 蔡柏蔷 | 2007 | 国际呼吸杂志2007，27，3： | 38 |
| 7 | 非小细胞肺癌内科治疗的现状显示文摘 | 郭其森 | 2009 | 中华肿瘤防治杂志2009，16，10： | 39 |
| 8 | 慢性阻塞性肺疾病诊断、处理和预防全球策略2013年版介绍显示文摘慢性阻塞性肺疾病全球倡议机构(The Global Initiative For Chronic Obstructive Lung Disease,GOLD)始建于1998年,并于2001年发表了第1版"慢性阻塞性肺疾病诊断、处理和预防全球策略"(简称慢阻肺全球策略),之后根据相应文献分别发表了2006和2011年版.2002年建立GOLD科学委员会,委员们负责汇集、评估慢阻肺相关文献并对策略进行更新.2013年GOLD科学委员会共检索到2011年7月1日至2012年12月中旬发表的符合条件的文献201篇,在充分研讨后采用其中30篇文献对慢阻肺全球策略2011年版进行部分更新,更新内容分为:(1)修订:需要新的参考文献对原文进行修订或添加新内容;(2)确定:对现有文献进行添加或替换;(3)对原文进行修改并给予解释说明.现将慢阻肺全球策略2013年版的主要修改内容简介如下. | 柳涛 蔡柏蔷 | 2013 | 中华结核和呼吸杂志2013，36，11： | 37 |
| 9 | Efficacy of prone position in acute respiratory distress syndrome patients: A pathophysiology-based review显示文摘Acute respiratory distress syndrome(ARDS) is a syndrome with heterogeneous underlying pathological processes. It represents a common clinical problem in intensive care unit patients and it is characterized by high mortality. The mainstay of treatment for ARDS is lung protective ventilation with low tidal volumes and positive end-expiratory pressure sufficient for alveolar recruitment. Prone positioning is a supplementary strategy available in managing patients with ARDS. It was first described 40 years ago and it proves to be in alignment with two major ARDS pathophysiological lung models; the 'sponge lung'- and the 'shape matching'-model. Current evidence strongly supports that prone positioning has beneficial effects on gas exchange, respiratory mechanics, lung protection and hemodynamics as it redistributes transpulmonary pressure, stress and strain throughout the lung and unloads the right ventricle. The factors that individually influence the time course of alveolar recruitment and the improvement in oxygenation during prone positioning have not been well characterized. Although patients' response to prone positioning is quite variable and hard to predict, large randomized trials and recent meta-analyses show that prone position in conjunction with a lung-protective strategy, when performed early and in sufficient duration, may improve survival in patients with ARDS. This pathophysiology-based review and recent clinical evidence strongly support the use of prone positioning in the early management of severe ARDS systematically and not as a rescue maneuver or a last-ditch effort. | Vasilios Koulouras Georgios Papathanakos Athanasios Papathanasiou Georgios Nakos | 2016 | World Journal of Critical Care Medicine2016，5，2： | 39 |
| 10 | Revisions to the Tumor,Node,Metastasis staging of lung cancer(8th edition):Rationale,radiologic findings and clinical implications显示文摘The Tumor, Node, Metastasis(TNM) staging system,adopted by the Union for International Cancer Control(UICC) and the American Joint Committee on Cancer(AJCC), has been recently revised, with the new 8^(th) edition of the staging manual being published in January 2017. This edition has few but important evidencebased changes to the TNM staging system used for lung cancer. Radiologists should be aware of the updated classification system to accurately provide staging information to oncologists and oncosurgeons. In this article, we discuss the rationale, illustrate the changes with relevance to Radiology, and review the clinical implications of the 8^(th) edition of the UICC/AJCC TNM staging system with regards to lung cancer. | Fernando U Kay Asha Kandathil Kiran Batra Sachin S Saboo Suhny Abbara Prabhakar Rajiah | 2017 | World Journal of Radiology2017，9，6： | 39 |
| 11 | Andrographolide sulfonate ameliorates lipopolysaccharide-induced acute lung injury in mice by down-regulating MAPK and NF-κB pathways显示文摘Acute lung injury(ALI) or acute respiratory distress syndrome(ARDS) is a severe, lifethreatening medical condition characterized by widespread inflammation in the lungs, and is a significant source of morbidity and mortality in the patient population. New therapies for the treatment of ALI are desperately needed. In the present study, we examined the effect of andrographolide sulfonate, a water-soluble form of andrographolide(trade name: Xi-Yan-Ping Injection), on lipopolysaccharide(LPS)-induced ALI and inflammation. Andrographolide sulfonate was administered by intraperitoneal injection to mice with LPS-induced ALI. LPS-induced airway inflammatory cell recruitment and lung histological alterations were significantly ameliorated by andrographolide sulfonate. Protein levels of pro-inflammatory cytokines in bronchoalveolar lavage fluid(BALF) and serum were reduced by andrographolide sulfonate administration. m RNA levels of pro-inflammatory cytokines in lung tissue were also suppressed. Moreover, andrographolide sulfonate markedly suppressed the activation of mitogen-activated protein kinase(MAPK) as well as p65 subunit of nuclear factor-κB(NF-κB). In summary, these results suggest that andrographolide sulfonate ameliorated LPS-induced ALI in mice by inhibiting NF-κB and MAPK-mediated inflammatory responses. Our study shows that water-soluble andrographolide sulfonate may represent a new therapeutic approach for treating inflammatory lung disorders. | Shuang Peng Nan Hang Wen Liu Wenjie Guo Chunhong Jiang Xiaoling Yang Qiang Xu Yang Sun | 2016 | Acta Pharmaceutica Sinica B2016，6，3： | 38 |
| 12 | Current oncologic applications of radiofrequency ablation therapies显示文摘Radiofrequency ablation (RFA) uses high frequency alternating current to heat a volume of tissue around a needle electrode to induce focal coagulative necrosis with minimal injury to surrounding tissues. RFA can be performed via an open, laparoscopic, or image guided percutaneous approach and be performed under general or local anesthesia. Advances in delivery mechanisms, electrode designs, and higher power generators have increased the maximum volume that can be ablated, while maximizing oncological outcomes. In general, RFA is used to control local tumor growth, prevent recurrence, palliate symptoms, and improve survival in a subset of patients that are not candidates for surgical resection. It's equivalence to surgical resection has yet to be proven in large randomized control trials. Currently, the use of RFA has been well described as a primary or adjuvant treatment modality of limited but unresectable hepatocellular carcinoma, liver metastasis, especially colorectal cancer metastases, primary lung tumors, renal cell carcinoma, boney metastasis and osteoid osteomas. The role of RFA in the primary treatment of early stage breast cancer is still evolving. This review will discuss the general features of RFA and outline its role in commonly encountered solid tumors. | Dhruvil R Shah Sari Green Angelina Elliot John P McGahan Vijay P Khatri | 2013 | World Journal of Gastrointestinal Oncology2013，5，4： | 33 |
| 13 | 对WHO 2004年版肺肿瘤组织学分类的体会显示文摘 | 滕晓东 | 2005 | 中华病理学杂志2005，34，8： | 31 |
| 14 | Experimental study of“Tong Xia”purgative method in ameliorating lung injury in acute necrotizing pancreatitis显示文摘AIM To investigate the role of tumor necrosisfactor(TNF)in lung injury during acutenecrotizing pancreatitis(ANP),and thetherapeutic effect of'Tong Xia'purgativemethod in minimizing the severity of lung injury.METHODS Fourteen canines were randomlydivided into 3 groups:the'Tong Xia'treatmentgroup(n = 5)using Dachengqitang;salinecontrol group(n = 5),and the sham operationgroup(n = 4).TNF activity in serum and inbronchoalveolar lavage fluid(BALF),the serumendotoxin levels were measured,and theseverity of lung injury evaluated.RESULTS Elevation of TNF activity was moreprominent in BALF than in serum.TNF activity inserum at 6 and 12 hours and in BALI:wassignificantly decreased in the'Tong Xia'treatment group than in the saline control one(q=21.11,q=12.07,q=9.03,respectively,P<0.01)and the lung injury was significantlyalleviated at 12 hours as compared with that inthe saline group,manifested as amelioration otthe lung wet/ dry weight ratio,decrease inprotein concentration and neutrophils count inBALF,and improvement of pulmonaryinflammatory changes.A positive correlationwas demonstrated between serum TNF activity and endotoxin level.CONCLUSION Hypersecretion of TNF is shownto be one of the major causes of lung injuryduring ANP;'Tong Xia'purgative method couldalleviate the degree of lung injury mediated byTNF. | Xia Q Jiang JM Gong X Chen GY Li L Huang ZW | 2000 | World Journal of Gastroenterology2000，6，1： | 31 |
| 15 | Therapeutic management options for stage Ⅲ non-small cell lung cancer显示文摘Lung cancer is the leading cause of cancer death worldwide.Majority of newly diagnosed lung cancers are non-small cell lung cancer(NSCLC), of which up to half are considered locally advanced at the time of diagnosis.Patients with locally advanced stage Ⅲ NSCLC consists of a heterogeneous population, making management for these patients complex.Surgery has long been the preferred local treatment for patients with resectable disease.For select patients, multimodality therapy involving systemic and radiation therapies in addition to surgery improves treatment outcomes compared to surgery alone.For patients with unresectable disease, concurrent chemoradiation is the preferred treatment.More recently, research into different chemotherapy agents, targeted therapies, radiation fractionation schedules, intensity-modulated radiotherapy, and proton therapy have shown promise to improve treatment outcomes and quality of life.The array of treatment approaches for locally advanced NSCLC is large and constantly evolving.An updated review of past and current literature for the roles of surgery, chemotherapeutic agents, radiation therapy, and targeted therapy for stage Ⅲ NSCLC patients are presented. | Stephanie M Yoon Talha Shaikh Mark Hallman | 2017 | World Journal of Clinical Oncology2017，8，1： | 32 |
| 16 | 慢性阻塞性肺疾病的康复医疗:评估与实施显示文摘2017年“慢性阻塞性肺疾病(慢阻肺)全球倡议”(global initiative for chronic obstructive lung disease,GOLD)中指出,慢阻肺是全球第四大致死疾病,2020年将会上升至第三位。2006年GOLD首次提出将肺康复作为慢阻肺稳定期非药物治疗的重要手段之一。 | 赵红梅 王辰 | 2018 | 中华结核和呼吸杂志2018，41，7： | 28 |
| 17 | 皮肌炎/多发性肌炎肺间质病变的临床及相关因素分析显示文摘 | 周亚欧 左晓霞 游运辉 罗卉 | 2005 | 中华风湿病学杂志2005，9，5： | 25 |
| 18 | 非小细胞肺癌治疗进展显示文摘 | 范江 姜格宁 | 2008 | 中华临床医师杂志(电子版)2008，2，1： | 25 |
| 19 | 非小细胞肺癌免疫治疗进展显示文摘近年来非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗进展主要体现以下两个方面:一是,对有明确驱动基因患者,进入个体化精准治疗时代:EGFR、ALK、ROS-1、C-MET等驱动基因突变/融合相应靶点的小分子抑制剂已成为这类患者的首选一线治疗;二是,对无明确驱动基因患者。 | 张为民 谢波 | 2019 | 实用医学杂志2019，35，4： | 25 |
| 20 | 肺泡上皮细胞功能特性与内毒素性急性肺损伤显示文摘 | 张秋金 李银平 黎檀实 | 2005 | 中国危重病急救医学2005，17，6： | 24 |
您所在的机构暂未开通此部分的功能，请联系管理员